Mannkind to triple Afrezza production

Danbury based Mannkind expects to triple the manufacturing of Afrezza, an inhalable form of insulin approved last summer by the FDA. DANBURY -- Executives with Mannkind are tripling their production capacity at their local manufacturing facility in the hopes that demand for their drug Afrezza will continue to increase in the coming months.

via Danbury Newswire http://ift.tt/1Ox0N7q